Therapy for Gastroenteropancreatic Neuroendocrine Tumors: drug evaluation reports review in Spain.

CONCLUSIONS: Everolimus and sunitinib are new drugs available for the treatment of GEP NET patients reported to have promising effects in advanced diseases. However, the reports are limited and thus new clinical studies on the impact of these drugs on clinical outcome, prognosis, financial burden and feasibility are necessary to support further recommendations. PMID: 30927758 [PubMed - as supplied by publisher]
Source: Neuroendocrinology Letters - Category: Endocrinology Tags: Neuro Endocrinol Lett Source Type: research